MaxVal announces that all of our software products and services now support the USPTO’s upcoming Private PAIR changes.
MaxVal’s E-Cigarettes report is now available through Patent LiveScape™, an analysis and reporting service that provides clients with interactive reports which extract actionable and predictive information. By leveraging data sciences best practices, MaxVal has constructed an interactive report that melds different yet related data sources into a comprehensive landscape, allowing the reader to dynamically explore relationships.
Following the publication of our recent Technology Landscape study on CRISPR-Cas9, MaxVal announces the latest advanced publication on the genome editing system, CRISPR, which has become an extremely important tool in medical research. The demonstration of the reprogrammable nature of Cas9 served as a catalyst to widespread adoption of CRISPR systems in biomedical and agricultural research. The potential benefits of CRISPR gene editing in several challenging diseases such as Alzheimer’s, cancer, and numerous autoimmune diseases are being explored by researchers.
MaxVal announces symphony® AI, the most advanced patent prosecution tool available on the market. It leverages the Salesforce Lightning architecture to integrate public and private data into a unique solution that provides decision guidance, predictions, and unprecedented insight into clients’ portfolios.
MaxVal announces the latest upgrade to its advanced, cloud-based IP management platform, symphony®.
Since its launch in 2016, symphony® has revolutionized IP management through its innovative use of Salesforce.com’s Lightning platform, delivering the industry’s most advanced workflow and automation capabilities; all in a highly configurable, intuitive system, designed for the modern IP department.
Although CRISPR was known to have an important role in bacterial immunity for over a decade, it is only in the last 5 years that it has garnered interest as a gene editing tool. Increasing investment in this field is indicative of global market opportunities for CRISPR-Cas9 over existing alternatives.
MaxVal is exhibiting at INTA 140th Annual meeting at Booth #418, to be held from May 19-23 at Washington State Convention Center, Seattle, WA.
MaxVal will be exhibiting at the AIPLA 2018 Spring Meeting at Booth #1 , on May 15-17, 2018 (The Westin Seattle in Seattle, WA).